Triumvira Immunologics

Adoptive Immunotherapy

Also additional effort Clin0 solid tumors; TAC-Claudin 18.2 RD/Clin0 multiple cancers; TAC-GPC3 RD hepatocellular carcinoma; TAC-GUCY2C RD multiple cancers; undisclosed RD undisclosed

Triumvira Immunologics is using T cell activation technology to engage the body’s natural defenses against cancer. Many tumors are difficult to treat and CAR-T and other T cell receptor (TCR) therapies have had safety concerns. They are addressing this with their T cell Antigen Coupler (TAC) technology which activates natural T cell function. TAC works directly with the TCR to prompt a T cell to recognize and attack cancer cells while retaining its natural mechanisms. Triumvira Immunologics has multiple product candidates with TAC101-CLDN18.2 being their lead clinical candidate. Preclinical data revealed TAC creates an efficient anti-tumor response and has a more favorable safety profile. Triumvira Immunologics is using this TAC technology to help patients defeat solid and liquid tumors.